Choosing Between TMS and Spravato
April 14, 2026
When depression doesn’t respond to traditional medications, it can feel exhausting to keep trying new options.
Two treatments that often come up in conversation are TMS and Spravato. They’re both used for treatment-resistant depression. They’re both delivered in medical settings. And they’re both considered when standard antidepressants haven’t provided enough relief.
But they work very differently.
Understanding those differences can help you approach the decision with more clarity and less pressure.
TMS (Transcranial Magnetic Stimulation) uses targeted magnetic pulses to stimulate specific areas of the brain involved in mood regulation.
Spravato, on the other hand, is a prescription nasal medication derived from ketamine. It works on the brain’s glutamate system rather than serotonin alone and is administered under medical supervision. Spravato is also FDA-approved specifically for treatment-resistant depression and depressive symptoms associated with suicidal thinking, which has contributed to its growing use when traditional antidepressants have not been effective.
One is stimulation-based.
One is medication-based.
Both aim to support people whose depression has remained persistent despite treatment, though their treatment structures and timelines can differ significantly.
TMS sessions are typically done five days a week for several weeks. You sit comfortably in a chair while a device delivers rhythmic pulses to the scalp.
Some people describe the sensation as tapping or light pressure. It can feel unusual at first, but most adjust quickly. You remain fully awake and can resume normal activities afterward.
Improvement tends to build gradually over time, with many individuals completing 20–36 sessions over four to six weeks before evaluating overall progress.
Spravato is administered as a nasal spray in the clinic. After each dose, you remain under observation for a period of time.
Some people describe temporary changes in perception, mild dissociation, or feeling slightly sedated. Others notice emotional quieting or relief from intensity. There is no “correct” experience.
Because Spravato affects perception temporarily, monitoring is required before you leave the clinic.
Spravato treatments typically occur twice per week during the initial phase, with sessions gradually becoming less frequent during maintenance. Compared to treatments that require frequent clinic visits throughout the week, some patients find this structure easier to integrate into work, school, or family schedules.
TMS usually requires several weeks of consistent sessions before improvement becomes noticeable.
Spravato may produce changes sooner for some individuals, with some patients reporting early shifts within the first few weeks of treatment. Because Spravato works through a different brain pathway than traditional antidepressants, some clinicians view it as a useful option when multiple medications have not provided adequate relief.
Faster isn’t always better. Sustainable progress depends on ongoing care, therapy, and follow-up — not just the initial shift.
Both treatments are considered safe when delivered appropriately and after proper screening.
TMS does not involve systemic medication. Side effects are typically mild and localized, such as headache or scalp discomfort.
Spravato can temporarily increase blood pressure or alter perception, which is why in-clinic monitoring is required. This monitoring process is part of the FDA safety protocol for Spravato and helps ensure that each treatment session is delivered in a controlled and supportive environment.
Before starting either treatment, providers review medical history, psychiatric stability, and risk factors.
Not everyone is a candidate for every option.
Choosing between TMS and Spravato isn’t about picking the “stronger” treatment. It’s about finding what fits your history, your symptoms, and your comfort level.
Some people prefer a non-medication approach like TMS. Others feel more comfortable with a medication-based treatment that may act more quickly or involve fewer weekly clinic visits during the initial treatment phase. Insurance coverage, prior treatment history, and scheduling flexibility can also influence the decision.
A thoughtful consultation can help sort through those variables without rushing the process.
Neither TMS nor Spravato is designed to stand alone.
Most people benefit from continuing therapy, medication management when appropriate, and consistent follow-up. Depression rarely resolves from a single intervention.
These treatments can create opportunity. Ongoing care helps turn that opportunity into stability.
Exploring advanced depression treatments can feel overwhelming, especially after previous disappointments.
At New Pathways Clinic, we approach these conversations with structure and realism. We focus on safety, education, and individualized planning rather than one-size-fits-all answers.
For individuals researching options like Spravato and TMS, a structured consultation can help clarify which approach may align best with your treatment history, current symptoms, and long-term care plan — without pressure.
Spravato is derived from ketamine but is formulated as an FDA-approved nasal medication for treatment-resistant depression. IV ketamine therapy is administered through infusion and follows a different protocol. While they affect similar brain pathways related to glutamate and neuroplasticity, their dosing structures and insurance pathways differ.
Spravato may produce symptom shifts sooner for some individuals, while TMS typically works gradually over several weeks of treatment. Response timelines vary from person to person, and improvement depends on multiple clinical factors. Early changes do not replace the need for continued support and monitoring.
In some cases, individuals explore different advanced treatments at different stages of care. Treatment transitions are made carefully and based on psychiatric evaluation, not frustration alone. Structured planning helps minimize risk and confusion.
TMS is generally associated with mild localized discomfort. Spravato may cause temporary perceptual changes or sedation that require observation. The better fit depends on individual medical history, treatment goals, and provider guidance rather than a universal comparison.
